1. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
    Nasreddine R, Florence E, Vandercam B, Moutschen M, Goffard JC, De Munter P, Delforge M, Marinus W, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH).AIDS. 2020 Jul 1;34(8):1151-1159. doi: 10.1097/QAD.0000000000002533.PMID: 32287063
  2. Incidence rate, predictors and outcomes of interruption of HIV care: nationwide results from the Belgian HIV cohort.
    Van Beckhoven D, Florence E, De Wit S, Wyndham-Thomas C, Sasse A, Van Oyen H, Macq J; Belgian Research on AIDS, HIV Consortium (BREACH).HIV Med. 2020 Oct;21(9):557-566. doi: 10.1111/hiv.12901. Epub 2020 Jul 5.
  3. Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
    De Wit S, Florence E, Vandekerckhove L, Vandercam B, Goffard JC, Van Wijngaerden E, Moutschen M, Demeester R, Thilakarathne P, Piryns H; BREACH* Consortium.
    Acta Clin Belg. 2018 Oct;73(5):341-347. doi: 10.1080/17843286.2018.1458428. Epub 2018 Apr 6.
  4. Late presentation to HIV testing is overestimated when based on the consensus definition.
    Sasse A, Florence E, Pharris A, De Wit S, Lacor P, Van Beckhoven D, Deblonde J, Delforge ML, Fransen K, Goffard JC, Legrand JC, Moutschen M, Piérard D, Ruelle J, Vaira D, Vandercam B, Van Ranst M, Van Wijngaerden E, Vandekerckhove L, Verhofstede C; Belgian Research AIDS & HIV Consortium (BREACH).
    HIV Med. 2016 Mar;17(3):231-4. doi: 10.1111/hiv.12292. Epub 2015 Jul 28.
  5. Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants.
    Van Beckhoven D, Florence E, Ruelle J, Deblonde J, Verhofstede C, Callens S, Vancutsem E, Lacor P, Demeester R, Goffard JC, Sasse A; BREACH Belgian Research on AIDS and HIV Consortium.
    BMC Infect Dis. 2015 Nov 3;15:496. doi: 10.1186/s12879-015-1230-3.